Loading
Stimuli-responsive Nanoparticle / Crispr/cas9 / Surface-modified Nanoparticle · Journal article
International Journal of Pharmaceutics: X · August 19, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing a barrier-oriented engineering framework for improving CRISPR/Cas9 delivery via nanoparticles. It identifies key biological obstacles (extracellular degradation, immune clearance, intracellular trafficking, nuclear entry) and surveys design strategies (ligand targeting, PEGylation, endosomal escape, stimulus-responsive release, nuclear localization optimization) without presenting original data or head-to-head efficacy comparisons. The review highlights unmet challenges—low intracellular delivery efficiency, imprecise targeting, and safety concerns—that currently limit clinical translation.
Narrative review.
Many CRISPR payloads fail to reach target sites due to extracellular degradation, immune clearance, and intracellular trafficking limitations. Proposed strategies include ligand-based surface modification, PEGylation and biomimetic coatings for circulation stability, and endosomal escape optimization. Stimulus-responsive nanoparticle systems and nuclear localization signal (NLS) optimization are highlighted as means to improve spatiotemporal control and genome-level editing efficiency.
No clinical trial data or safety/efficacy outcomes in human subjects. Major challenges persist: limited intracellular delivery efficiency, insufficient targeting precision, and safety concerns that hinder clinical translation.
The source did not state who this applies to in practice.
This is a narrative review proposing conceptual frameworks for nanoparticle-mediated CRISPR delivery; it does not report primary experimental data, efficacy outcomes, or comparative evidence.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) has emerged as a promising gene-editing platform for genetic disorders; however, its in vivo application remains limited by low delivery efficiency and biological barriers. Many CRISPR payloads fail to reach target sites due to extracellular degradation, immune clearance, and intracellular trafficking limitations. This review examines the interplay between biological barriers and nanoparticle engineering strategies for CRISPR/Cas9 delivery. A barrier-oriented engineering approach is proposed as a central framework, encompassing ligand-based surface modification for enhanced targeting and uptake, improved circulation stability via PEGylation and biomimetic coatings, and optimized payload release through endosomal escape strategies. Stimulus-responsive nanoparticle systems further enable spatiotemporal control over payload release. Nuclear targeting strategies, including optimization of nuclear localization signals (NLS) and exploitation of endogenous trafficking pathways, are highlighted as key factors for improving genome-level editing efficiency. Despite these advances, major challenges-including limited intracellular delivery efficiency, insufficient targeting precision, and safety concerns-continue to hinder clinical translation. Future directions highlight artificial intelligence-driven nanoparticle design, personalized delivery systems, and next-generation CRISPR platforms. Overall, an integrated, barrier-oriented engineering strategy is essential for advancing CRISPR/Cas9 delivery toward clinical applications, ultimately advancing global good health and well-being.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.